⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28239781 | 0.97 | — | — | |
| SCHEMBL344476 | 0.81 | — | — | |
| SCHEMBL27905686 | 0.78 | — | — | |
| SCHEMBL1042894 | 0.72 | — | — | |
| SCHEMBL27574206 | 0.71 | — | — | |
| SCHEMBL11743331 | 0.69 | — | — | |
| SCHEMBL18229252 | 0.69 | HTR1A (0.36) | — | |
| SCHEMBL10913606 | 0.67 | — | — | |
| SCHEMBL15321068 | 0.67 | — | — | |
| SCHEMBL8173001 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116783204-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| CN-112533951-A | anti-MSR 1 antibodies and methods of use thereof | 里珍纳龙药品有限公司 | 2021-03-19 | — | — | CN | disclosed |
| CN-108295073-B | Polyfluoro compounds as bruton's tyrosine kinase inhibitors | 浙江导明医药科技有限公司 | 2020-06-16 | — | — | CN | disclosed |
| US-20200101061-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2020-04-02 | — | — | US | disclosed |
| EP-3406596-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | Japan Tobacco Inc. (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-20180265454-A1 | Method for Producing 4-Oxoquinoline Compound | JAPAN TOBACCO INC. (JP) | 2018-09-20 | — | — | US | disclosed |
| US-20150299104-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-1992607-B9 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC (JP) | 2015-07-01 | — | — | EP | disclosed |
| US-20150174117-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. | 2015-06-25 | — | — | US | disclosed |
| EP-1992607-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | Japan Tobacco, Inc. (JP) | 2008-11-19 | — | — | EP | disclosed |
| CN-100375742-C | 4-oxoquinoline compounds and utilization thereof as HIV integrase inhibitors | JAPAN TOBACCO INC (JP) | 2008-03-19 | — | — | CN | disclosed |
| US-7176220-B2 | 4-oxoquinoline compound and use thereof as pharmaceutical agent | JAPAN TOBACCO INC. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20060217413-A1 | 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-04-20 | — | — | US | disclosed |
| CN-1692101-A | 4-oxoquinoline compounds and utilization thereof as HIV integrase inhibitors | JAPAN TOBACCO INC (JP) | 2005-11-02 | — | — | CN | disclosed |
| US-20050239819-A1 | 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1564210-A1 | 4-OXOQUINOLINE COMPOUNDS AND UTILIZATION THEREOF AS HIV INTEGRASE INHIBITORS | JAPAN TOBACCO INC. (JP) | 2005-08-17 | — | — | EP | disclosed |
| EP-1490341-A1 | NOVEL ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080579-A1 | NOVEL ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | WO | disclosed |